Antibody profile in patients with inflammatory bowel diseases

Nizhegorodova D.B., Adamovich A.Yu., Ivanchyk G.I., Dybov O.G., Kulinich S.S., Shadrina V.K., Vorobei A.V., Zafranskaya M.M.

Belarusian Medical Academy of Post-Graduated Education, Minsk, Republic of Belarus

Currently, there is no clear-cut idea about the use of specific antibodies panel for predicting inflammatory bowel disease (IBD) as well as IBD progression and the therapeutic effect. The combination of serologic biomarkers with clinical, endoscopic, histologic, radiologic, genetic and microbiologic parameters may be ideal basis for a personalized approach in IBD diagnosis and treatment. The aim of this work was to determine the serological profile in patients with Crohn's disease (CD) and ulcerative colitis (UC) for potential biomarkers identification. The changes in immunoglobulins’ production as well as specific antiglycan antibodies (ASCA) and autoantibodies to neutrophil components (pANCA) were revealed in IBD patients: the serological profile ASCA+/pANCA- was determined in 67% of CD patients, and in 100% ASCA-/pANCA+ corresponded to that of UC patients. The combination of ASCA and pANCA antibodies has been shown to be useful for the differential diagnosis of CD and UC, while the determination of pANCA titer is diagnostically significant when assessing IBD progression.